(4-((dimethylamino)methyl)phenyl)(4-isopropylpiperazin-1-yl)methanone | 748132-05-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-((dimethylamino)methyl)phenyl)(4-isopropylpiperazin-1-yl)methanone
• 英文别名: [4-[(Dimethylamino)methyl]phenyl]-(4-propan-2-ylpiperazin-1-yl)methanone
• CAS: 748132-05-0
• 化学式: C₁₇H₂₇N₃O
• 分子量: 289.421
• InChiKey: WTYYDZCVDBXKMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  26.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  tert-butyl 4-(4-formylbenzoyl)piperazine-1-carboxylate 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 6.5h， 生成 (4-((dimethylamino)methyl)phenyl)(4-isopropylpiperazin-1-yl)methanone
  参考文献：
  名称：

  Novel Benzamide-Based Histamine H3 Receptor Antagonists: The Identification of Two Candidates for Clinical Development

  摘要：

  The preclinical characterization of novel phenyl(piperazin-1-yl)methanones that are histamine H-3 receptor antagonists is described. The compounds described are high affinity histamine H-3 antagonists. Optimization of the physical properties of these histamine H-3 antagonists led to the discovery of several promising lead compounds, and extensive preclinical profiling aided in the identification of compounds with optimal duration of action for wake promoting activity. This led to the discovery of two development candidates for Phase I and Phase II clinical trials.

  DOI：

  10.1021/ml5005156

文献信息

• PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES
  申请人：Apodaca L. Richard

  公开号：US20080056991A1

  公开（公告）日：2008-03-06

  Substituted piperazinyl and diazepanyl benzamides and benzthioamides of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

  本发明涉及公式（I）的替代哌嗪基和二氮杂环基苯甲酰胺和苯硫酰胺，包含它们的组合物以及使用它们治疗组胺介导的疾病的方法。
• US7414047B2
  申请人：——

  公开号：US7414047B2

  公开（公告）日：2008-08-19
• Novel Benzamide-Based Histamine H3 Receptor Antagonists: The Identification of Two Candidates for Clinical Development
  作者：Michael A. Letavic、Leah Aluisio、Richard Apodaca、Manoj Bajpai、Ann J. Barbier、Anne Bonneville、Pascal Bonaventure、Nicholas I. Carruthers、Christine Dugovic、Ian C. Fraser、Michelle L. Kramer、Brian Lord、Timothy W. Lovenberg、Lilian Y. Li、Kiev S. Ly、Heather Mcallister、Neelakandha S. Mani、Kirsten L. Morton、Anthony Ndifor、S. Diane Nepomuceno、Chennagiri R. Pandit、Steven B. Sands、Chandra R. Shah、Jonathan E. Shelton、Sandra S. Snook、Devin M. Swanson、Wei Xiao

  DOI：10.1021/ml5005156

  日期：2015.4.9

  The preclinical characterization of novel phenyl(piperazin-1-yl)methanones that are histamine H-3 receptor antagonists is described. The compounds described are high affinity histamine H-3 antagonists. Optimization of the physical properties of these histamine H-3 antagonists led to the discovery of several promising lead compounds, and extensive preclinical profiling aided in the identification of compounds with optimal duration of action for wake promoting activity. This led to the discovery of two development candidates for Phase I and Phase II clinical trials.